GlassScriptPhysician profile
Gabor Benda
NPI 1619996840
$1,580.50
in general payments reported to CMS, 2019-2025
19 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.61 · 2020: $500 · 2021: $112 · 2022: $145 · 2023: $265 · 2024: $292 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $500.00 | 2020 | |
| Abbvie INC. | $206.95 | 2021-2025 | |
| Pfizer INC. | $138.44 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $126.97 | 2023-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $109.02 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $104.44 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Sanofi Pasteur INC. | $61.11 | 2022-2023 | |
| Exact Sciences Corporation | $60.83 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $35.26 | 2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $34.18 | 2023 | Trelegy Ellipta, Bexsero, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.52 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $32.91 | 2021-2022 | |
| Astellas Pharma US INC | $29.82 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $27.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.06 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.95 | 2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $16.05 | 2025 | Invega Sustenna |
| Novartis Pharmaceuticals Corporation | $15.33 | 2023 | |
| Nevro Corp. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabor Benda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.